First Trust NYSE Arca Biotechnology Index Fund (FBT)
An exchange-traded fund listed on AMEX. A fund is not a company: it has no filed accounts of its own here, and it is never ranked beside companies. Every figure below is market data, with the day it was supplied.
Price
Last close 268.39 USD on Oct 15, 2026. Market data, supplied Oct 15, 2026.
What it costs
| Expense ratio | 0.55% |
| Assets under management | 2.85B USD |
| Net asset value per share | 259.54 USD |
| Inception | Jun 19, 2006 |
| Sponsor | First Trust |
| Asset class | Sector Equity |
| Holdings the fund reports | 30 |
Market data, supplied Oct 15, 2026.
What it holds
The largest 25 by weight of the 31 holdings in the snapshot of Oct 14, 2026. A fund is marked as a fund, and a holding that is not a company's share (a bond, a bill, cash, an option or a swap) is marked as not a company.
| # | Holding | Weight |
|---|---|---|
| 1 | Natera, Inc. | 4.69% |
| 2 | Halozyme Therapeutics, Inc. | 4.60% |
| 3 | Illumina, Inc. | 4.56% |
| 4 | Corcept Therapeutics Inc. | 4.10% |
| 5 | Genmab A/S (ADR) | 4.03% |
| 6 | Repligen Corporation | 3.89% |
| 7 | NeoGenomics, Inc. | 3.78% |
| 8 | BeOne Medicines Ltd. (ADR) | 3.74% |
| 9 | Biogen Inc. | 3.68% |
| 10 | Gilead Sciences, Inc. | 3.64% |
| 11 | Amgen Inc. | 3.63% |
| 12 | ADMA Biologics, Inc. | 3.63% |
| 13 | Regeneron Pharmaceuticals, Inc. | 3.63% |
| 14 | Exelixis, Inc. | 3.37% |
| 15 | Bio-Techne Corporation | 3.25% |
| 16 | Vertex Pharmaceuticals Incorporated | 3.20% |
| 17 | United Therapeutics Corporation | 3.18% |
| 18 | BioNTech SE (ADR) | 3.11% |
| 19 | TG Therapeutics, Inc. | 3.04% |
| 20 | Bruker Corporation | 2.99% |
| 21 | Incyte Corporation | 2.98% |
| 22 | BioMarin Pharmaceutical Inc. | 2.94% |
| 23 | argenx SE (ADR) | 2.93% |
| 24 | Sarepta Therapeutics, Inc. | 2.79% |
| 25 | Madrigal Pharmaceuticals, Inc. | 2.69% |
Market data, supplied Oct 15, 2026.
Sector weights
| Healthcare | 100.00% |
Market data, supplied Oct 15, 2026.
Country weights
| United States | 83.50% |
| Denmark | 4.00% |
| Switzerland | 3.71% |
| Germany | 3.32% |
| Netherlands | 2.94% |
| Ireland | 2.45% |
| Other | 0.08% |
Market data, supplied Oct 15, 2026.
Look-through value
Earnings yield, P/E and book yield of the holdings taken together: n/a. Look-through figures are not measured for this fund yet.